INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of West Pharmaceutical Services

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against West Pharmaceutical Services, Inc. due to allegations of false and misleading statements regarding the company's financial health and operational challenges, particularly related to its High-Value Products portfolio and SmartDose device [2][4]. Group 1: Allegations Against West Pharmaceutical Services - The complaint alleges that West and its executives violated federal securities laws by making false statements and failing to disclose significant destocking issues in their High-Value Products portfolio [4]. - It is claimed that the SmartDose device, which was marketed as a high-margin growth product, actually diluted profit margins due to operational inefficiencies [4]. - The allegations also include that these margin pressures could lead to costly restructuring activities, including the exit from continuous glucose monitoring contracts with long-standing customers [4]. Group 2: Impact of Disclosures - The truth about the alleged fraud was revealed through a series of disclosures, culminating on February 13, 2025, when West issued weak revenue and earnings forecasts for 2025 [5]. - West attributed the disappointing guidance to contract manufacturing challenges, including the loss of two major customers transitioning to in-house manufacturing [5]. - Following this news, West's stock price dropped by $123.17 per share, a decline of 38%, closing at $199.11 on February 13, 2025 [5]. Group 3: Legal Proceedings and Investor Actions - Investors who suffered losses exceeding $100,000 between February 16, 2023, and February 12, 2025, are encouraged to contact Faruqi & Faruqi to discuss their legal options [1]. - There is a deadline of July 7, 2025, for investors to seek the role of lead plaintiff in the federal securities class action against West [2][6]. - The lead plaintiff is defined as the investor with the largest financial interest in the relief sought, who will oversee the litigation on behalf of the class [6].